A systematic review of 23 studies on mobile health nutrition interventions in adults with chronic kidney disease pooled eight controlled studies in dialysis patients and found no significant effects on biochemical markers or interdialytic weight gain. Pre-post studies reported lower sodium intake and blood pressure, but without concurrent control groups, those changes cannot be credited to the apps or messaging tools themselves.
The real takeaway is how thin the evidence is. Only eight of 23 studies were suitable for pooling, and dialysis populations dominated the quantitative synthesis, so the results say little about earlier-stage CKD, where dietary sodium, protein and phosphorus control may matter most for slowing progression. Null findings on potassium, phosphate and fluid gain are plausible: dialysis patients face rigid, clinic-managed regimens, leaving less room for a smartphone nudge to add value. The encouraging pre-post signals fit a familiar pattern in digital health, where early uncontrolled studies look promising and rigorous trials shrink the effect. Regression to the mean, attention effects and temporal change all inflate before-and-after results. Small trials with short follow-up likely limit power as well. For patients, apps remain a reasonable adjunct for tracking sodium and fluids, but nothing here shows they improve clinical outcomes or substitute for renal dietitian support. This analysis is confirmatory of cautious expectations rather than paradigm-shifting; adequately powered randomized trials with hard endpoints such as kidney function decline, hospitalization and blood pressure are the missing piece.